@article{quigley_relative_2015-1,
	title = {Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis {C}-infected patients in a {Japanese} population: {A} {Bayesian} network meta-analysis},
	volume = {45},
	issn = {1386-6346},
	shorttitle = {Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis {C}-infected patients in a {Japanese} population},
	doi = {10.1111/hepr.12467},
	abstract = {AIM: Simeprevir (SMV) is an oral, once-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. In phase II/III randomized controlled trials (RCT) conducted in Japan, SMV, in combination with peginterferon-α and ribavirin (PEG IFN/RBV), demonstrated potent efficacy in HCV genotype 1-infected patients relative to PEG IFN/RBV and was generally well tolerated. Telaprevir (TVR) in combination with PEG IFN/RBV is licensed for the treatment of HCV in Japan. In the absence of head-to-head comparisons of TVR and SMV in a Japanese population, we undertook a network meta-analysis (NMA) to examine the relative efficacy and safety of SMV and TVR in combination with PEG IFN/RBV. METHODS: A systematic review identified SMV and TVR RCT in Japanese treatment-naïve patients. Bayesian NMA was performed assuming fixed study effects. RESULTS: Three studies met our inclusion criteria: two SMV and one TVR. SMV showed a higher mean odds ratio (OR) of achieving SVR versus TVR (OR, 1.68 (95\% credible interval 0.66-4.26)). SMV showed a lower mean OR of discontinuation: overall, 0.35 (0.12-1.00); and due to AE, 0.87 (0.23-3.34) versus TVR. SMV showed a lower mean OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.41 (0.17-0.99) but a higher mean OR of experiencing pruritus 1.26 (0.46-3.47) versus TVR. CONCLUSION: In this indirect treatment comparison, SMV, in combination with PEG IFN/RBV, showed a favorable risk-benefit profile compared with TVR with PEG IFN/RBV in Japanese treatment-naïve HCV patients.},
	language = {eng},
	number = {10},
	journal = {Hepatology Research: The Official Journal of the Japan Society of Hepatology},
	author = {Quigley, J. M. and Bryden, P. A. and Scott, D. A. and Kuwabara, H. and Cerri, K.},
	month = oct,
	year = {2015},
	pmid = {25559771},
	keywords = {hepatitis C, network meta-analysis, simeprevir, telaprevir},
	pages = {E89--98},
}

{"_id":"JZaZ2Seh9Q2365Aon","bibbaseid":"quigley-bryden-scott-kuwabara-cerri-relativeefficacyandsafetyofsimeprevirandtelaprevirintreatmentnavehepatitiscinfectedpatientsinajapanesepopulationabayesiannetworkmetaanalysis-2015","authorIDs":[],"author_short":["Quigley, J. M.","Bryden, P. A.","Scott, D. A.","Kuwabara, H.","Cerri, K."],"bibdata":{"bibtype":"article","type":"article","title":"Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis","volume":"45","issn":"1386-6346","shorttitle":"Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population","doi":"10.1111/hepr.12467","abstract":"AIM: Simeprevir (SMV) is an oral, once-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. In phase II/III randomized controlled trials (RCT) conducted in Japan, SMV, in combination with peginterferon-α and ribavirin (PEG IFN/RBV), demonstrated potent efficacy in HCV genotype 1-infected patients relative to PEG IFN/RBV and was generally well tolerated. Telaprevir (TVR) in combination with PEG IFN/RBV is licensed for the treatment of HCV in Japan. In the absence of head-to-head comparisons of TVR and SMV in a Japanese population, we undertook a network meta-analysis (NMA) to examine the relative efficacy and safety of SMV and TVR in combination with PEG IFN/RBV. METHODS: A systematic review identified SMV and TVR RCT in Japanese treatment-naïve patients. Bayesian NMA was performed assuming fixed study effects. RESULTS: Three studies met our inclusion criteria: two SMV and one TVR. SMV showed a higher mean odds ratio (OR) of achieving SVR versus TVR (OR, 1.68 (95% credible interval 0.66-4.26)). SMV showed a lower mean OR of discontinuation: overall, 0.35 (0.12-1.00); and due to AE, 0.87 (0.23-3.34) versus TVR. SMV showed a lower mean OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.41 (0.17-0.99) but a higher mean OR of experiencing pruritus 1.26 (0.46-3.47) versus TVR. CONCLUSION: In this indirect treatment comparison, SMV, in combination with PEG IFN/RBV, showed a favorable risk-benefit profile compared with TVR with PEG IFN/RBV in Japanese treatment-naïve HCV patients.","language":"eng","number":"10","journal":"Hepatology Research: The Official Journal of the Japan Society of Hepatology","author":[{"propositions":[],"lastnames":["Quigley"],"firstnames":["J.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Bryden"],"firstnames":["P.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Scott"],"firstnames":["D.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Kuwabara"],"firstnames":["H."],"suffixes":[]},{"propositions":[],"lastnames":["Cerri"],"firstnames":["K."],"suffixes":[]}],"month":"October","year":"2015","pmid":"25559771","keywords":"hepatitis C, network meta-analysis, simeprevir, telaprevir","pages":"E89–98","bibtex":"@article{quigley_relative_2015-1,\n\ttitle = {Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis {C}-infected patients in a {Japanese} population: {A} {Bayesian} network meta-analysis},\n\tvolume = {45},\n\tissn = {1386-6346},\n\tshorttitle = {Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis {C}-infected patients in a {Japanese} population},\n\tdoi = {10.1111/hepr.12467},\n\tabstract = {AIM: Simeprevir (SMV) is an oral, once-daily protease inhibitor for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection. In phase II/III randomized controlled trials (RCT) conducted in Japan, SMV, in combination with peginterferon-α and ribavirin (PEG IFN/RBV), demonstrated potent efficacy in HCV genotype 1-infected patients relative to PEG IFN/RBV and was generally well tolerated. Telaprevir (TVR) in combination with PEG IFN/RBV is licensed for the treatment of HCV in Japan. In the absence of head-to-head comparisons of TVR and SMV in a Japanese population, we undertook a network meta-analysis (NMA) to examine the relative efficacy and safety of SMV and TVR in combination with PEG IFN/RBV. METHODS: A systematic review identified SMV and TVR RCT in Japanese treatment-naïve patients. Bayesian NMA was performed assuming fixed study effects. RESULTS: Three studies met our inclusion criteria: two SMV and one TVR. SMV showed a higher mean odds ratio (OR) of achieving SVR versus TVR (OR, 1.68 (95\\% credible interval 0.66-4.26)). SMV showed a lower mean OR of discontinuation: overall, 0.35 (0.12-1.00); and due to AE, 0.87 (0.23-3.34) versus TVR. SMV showed a lower mean OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.41 (0.17-0.99) but a higher mean OR of experiencing pruritus 1.26 (0.46-3.47) versus TVR. CONCLUSION: In this indirect treatment comparison, SMV, in combination with PEG IFN/RBV, showed a favorable risk-benefit profile compared with TVR with PEG IFN/RBV in Japanese treatment-naïve HCV patients.},\n\tlanguage = {eng},\n\tnumber = {10},\n\tjournal = {Hepatology Research: The Official Journal of the Japan Society of Hepatology},\n\tauthor = {Quigley, J. M. and Bryden, P. A. and Scott, D. A. and Kuwabara, H. and Cerri, K.},\n\tmonth = oct,\n\tyear = {2015},\n\tpmid = {25559771},\n\tkeywords = {hepatitis C, network meta-analysis, simeprevir, telaprevir},\n\tpages = {E89--98},\n}\n\n","author_short":["Quigley, J. M.","Bryden, P. A.","Scott, D. A.","Kuwabara, H.","Cerri, K."],"bibbaseid":"quigley-bryden-scott-kuwabara-cerri-relativeefficacyandsafetyofsimeprevirandtelaprevirintreatmentnavehepatitiscinfectedpatientsinajapanesepopulationabayesiannetworkmetaanalysis-2015","role":"author","urls":{},"keyword":["hepatitis C","network meta-analysis","simeprevir","telaprevir"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/f/FfNE7kWA6pCvwcJZF/myPubs.bib","creationDate":"2019-11-10T12:58:11.689Z","downloads":0,"keywords":["hepatitis c","network meta-analysis","simeprevir","telaprevir"],"search_terms":["relative","efficacy","safety","simeprevir","telaprevir","treatment","hepatitis","infected","patients","japanese","population","bayesian","network","meta","analysis","quigley","bryden","scott","kuwabara","cerri"],"title":"Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis","year":2015,"dataSources":["usc9shidSEoJgjLwM","ZaHtWavQhcwZqKLNF","iRRNaRs6FkffgErta","zeMwFvgpdRkYAkfoD","v8uQmZsBpiqycmskv"]}